HU6: Difference between revisions
Content deleted Content added
m Open access bot: doi updated in citation with #oabot. |
+ chembox |
||
| Line 1: | Line 1: | ||
{{Chembox |
|||
| ⚫ | '''HU6''' is a [[prodrug]] of the mitochondrial [[uncoupler]] [[2,4-dinitrophenol]] (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider [[therapeutic index]] and improve safety." Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for [[metabolic dysfunction-associated steatohepatitis]]. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly.<ref>{{cite journal |last1=Harrison |first1=Stephen A. |last2=Loomba |first2=Rohit |last3=Dubourg |first3=Julie |last4=Ratziu |first4=Vlad |last5=Noureddin |first5=Mazen |title=Clinical Trial Landscape in NASH |journal=Clinical Gastroenterology and Hepatology |date=July 2023 |volume=21 |issue=8 |pages=2001–2014 |doi=10.1016/j.cgh.2023.03.041}}</ref><ref>{{cite journal |last1=Noureddin |first1=Mazen |last2=Khan |first2=Shaharyar |last3=Portell |first3=Francisco |last4=Jorkasky |first4=Diane |last5=Dennis |first5=Jameel |last6=Khan |first6=Omer |last7=Johansson |first7=Lars |last8=Johansson |first8=Edvin |last9=Sanyal |first9=Arun J |title=Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial |journal=The Lancet Gastroenterology & Hepatology |date=December 2023 |volume=8 |issue=12 |pages=1094–1105 |doi=10.1016/S2468-1253(23)00198-X|doi-access=free }}</ref> A phase 2b trial was launched in late 2023.<ref>{{cite news |title=Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments |url=https://finance.yahoo.com/news/rivus-pharmaceuticals-announces-expansion-hu6-130000050.html |access-date=3 December 2023 |work=Yahoo Finance |date=15 November 2023}}</ref> |
||
| Section1 = {{Chembox Identifiers |
|||
|PubChem=135205989 |
|||
}} |
|||
| ⚫ | }}'''HU6''' is a [[prodrug]] of the mitochondrial [[uncoupler]] [[2,4-dinitrophenol]] (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider [[therapeutic index]] and improve safety." Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for [[metabolic dysfunction-associated steatohepatitis]]. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly.<ref>{{cite journal |last1=Harrison |first1=Stephen A. |last2=Loomba |first2=Rohit |last3=Dubourg |first3=Julie |last4=Ratziu |first4=Vlad |last5=Noureddin |first5=Mazen |title=Clinical Trial Landscape in NASH |journal=Clinical Gastroenterology and Hepatology |date=July 2023 |volume=21 |issue=8 |pages=2001–2014 |doi=10.1016/j.cgh.2023.03.041}}</ref><ref>{{cite journal |last1=Noureddin |first1=Mazen |last2=Khan |first2=Shaharyar |last3=Portell |first3=Francisco |last4=Jorkasky |first4=Diane |last5=Dennis |first5=Jameel |last6=Khan |first6=Omer |last7=Johansson |first7=Lars |last8=Johansson |first8=Edvin |last9=Sanyal |first9=Arun J |title=Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial |journal=The Lancet Gastroenterology & Hepatology |date=December 2023 |volume=8 |issue=12 |pages=1094–1105 |doi=10.1016/S2468-1253(23)00198-X|doi-access=free }}</ref> A phase 2b trial was launched in late 2023.<ref>{{cite news |title=Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments |url=https://finance.yahoo.com/news/rivus-pharmaceuticals-announces-expansion-hu6-130000050.html |access-date=3 December 2023 |work=Yahoo Finance |date=15 November 2023}}</ref> |
||
==References== |
==References== |
||
{{reflist}} |
{{reflist}} |
||
Revision as of 16:28, 25 February 2024
| Identifiers | |
|---|---|
PubChem CID
|
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
HU6 is a prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider therapeutic index and improve safety." Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for metabolic dysfunction-associated steatohepatitis. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly.[1][2] A phase 2b trial was launched in late 2023.[3]
References
- ^ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen (July 2023). "Clinical Trial Landscape in NASH". Clinical Gastroenterology and Hepatology. 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041.
- ^ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J (December 2023). "Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial". The Lancet Gastroenterology & Hepatology. 8 (12): 1094–1105. doi:10.1016/S2468-1253(23)00198-X.
- ^ "Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments". Yahoo Finance. 15 November 2023. Retrieved 3 December 2023.